Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a trial of JNJ-64304500 in alopecia areata
jRCT2031200401Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata, alopecia areata totalis (AT) and alopecia universalis (AU) comparing JNJ-64304500 with Placebo (2 arms). Primary endpoint: Percentage of participants achieving SALT90 response at Week 24. Started May 2021; status: active, not recruiting.
02
Drugs
NNC0142-0002
03
Conditions
alopecia areataalopecia areata totalis (AT)alopecia universalis (AU)
Beyond the preview
Go deeper on jRCT2031200401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200401.